Clinical Trials Logo
  1. Home
  2. Helicobacter Pylori
  3. NCT03716622

A Comparison of Clarithromycin-based and Furazolidone-based Bismuth-containing Regimens for H. Pylori Eradication

Helicobacter Pylori Clinical Trial

Official title:
A Comparison of Clarithromycin-based and Furazolidone-based Bismuth-containing Regimens for H. Pylori Eradication

Clinical Trial Summary

We aim to assess and compare the effectiveness of clarithromycin- and furazolidone-based regimens as primary therapies in eradicating H. pylori.

Clinical Trial Description

Helicobacter pylori plays a pivotal role in many diseases such as peptic ulcer disease and MALT lymphomas. And the prevalence of H. pylori is increasing in some parts of the world.

However, the eradication becomes increasingly difficult due to the growing antibiotic resistance. Bismuth-containing quadruple regimens are now recommended to serve as first-line therapies. Bismuth-clarithromycin-containing and bismuth-furazolidone-containing quadruple regimens are both in the list of the first regimens. And recent antimicrobial susceptibility tests showed us that the clarithromycin was increasingly resisted while furazolidone remained hardly resisted. The comparison between the effects of bismuth-clarithromycin-containing and bismuth-furazolidone-containing quadruple regimens is not so clear. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03716622
Study type Interventional
Source Shandong University
Contact
Status Completed
Phase Phase 4
Start date July 31, 2018
Completion date August 31, 2019
View Details
See also
  Status Clinical Trial Phase
Completed NCT02892409 - TAK-438 Bismuth Drug Interaction Study Phase 1
Completed NCT05073367 - A Study Reviewing Medical Records of Adults With Helicobacter Pylori Infections in China
Completed NCT00596401 - The Preventive Effect of Helicobacter Pylori Eradication on the Development of Gastric Cancer
Not yet recruiting NCT04101708 - A Comparison of High-dose Dual Therapy and Half-dose Clarithromycin-containing Bismuth Quadruple Therapy for H.P Eradication in Elderly Patients Phase 4
Recruiting NCT04029493 - The Situation of Re-infection of Helicobacter Pylori After Successful Eradication
Recruiting NCT04029415 - The Study of the Antimicrobial Resistance of Helicobacter Pylori in Shandong Province
Recruiting NCT04030715 - The Associations Between the Gastric Mucosal Pathology and the Eradication Rate of H.Pylori :A Multicenter Study N/A
Not yet recruiting NCT02934048 - Optimal Duration of Antimicrobial Susceptibility Test (AST) Guided Rescue Therapy for Helicobacter Pylori Infection Phase 4
Not yet recruiting NCT02933229 - The Influence of Helicobacter Pylori Eradication on Gastric Pathology: a Long-term, Prospective Cohort Study Phase 4
Recruiting NCT05184491 - Nitazoxanide and Lansoprazole Based Regimens for H. Pylori Management Phase 4
Recruiting NCT05790525 - Effect of Oral Helicobacter Pylori Infection on the Efficacy of Gastroluminal Helicobacter Pylori Eradication Therapy Phase 4
Completed NCT05790512 - Association of Oral Helicobacter Pylori Infection With Gastric Helicobacter Pylori Infection
Recruiting NCT05276557 - PyloPlus Urea Breath Test System Pediatric Safety and Efficacy Study Phase 3
Recruiting NCT03177629 - H. Pylori Eradication for Moderate ITP Phase 3
Recruiting NCT05053945 - Helicobacter Pylori, Atrophic Gastritis and Intestinal Metaplasia Registry and Prospective Study
Recruiting NCT05449028 - Helicobacter Pylori Eradication Therapy in Portugal N/A
Recruiting NCT00306280 - Feasibility Study of Phototherapy System to Treat H Pylori N/A
Active, not recruiting NCT02675010 - Value of Additional Corpus Biopsy for Diagnosis of H Pylori in Atrophic Gastritis. Prospective Non-randomized Study N/A
Withdrawn NCT00467155 - Helicobacter in The Gambia (Part 2) N/A
Not yet recruiting NCT04937426 - Development of a Laboratory Test for the Detection of a Fluorescent-labeled Urease Inhibitor Marker Attached to Helicobacter Pylori N/A